• Welcome to Renmin Hospital of Wuhan University
  • 网站首页 中文版 English Francaise
  • 林丹丹 肿瘤
    肿瘤Ⅲ科副主任,主任医师,副教授,硕士生导师
    A+ A-
    导师介绍

    姓名 林丹丹
    出生年月 1986年2月
    单位 武汉大学人民医院肿瘤III科
    所属学科 临床医学-肿瘤学
    职务、职称及头衔 肿瘤III科副主任,主任医师,副教授,硕士生导师
    E-mail  236772452@qq.co
    联系方式 13871180043
    研究方向 1.肿瘤免疫微环境与免疫治疗
    2.消化道肿瘤、肺癌靶向干预与分子调控
    个人简介 主要研究方向为肿瘤内科治疗与肿瘤免疫微环境调节机制。先后赴美国芝加哥大学2011,美国德州西南医学中心2017-2018,北京医科院肿瘤医院2020等国内外顶尖临床诊疗与基础研究机构学习研修,临床经验丰富。主要研究肿瘤免疫微环境与免疫治疗,主持国家自然科学基金3项,参与科技部重点研发计划1项,总经费超过200万元。实验室团队及实验条件成熟,主要通过小鼠炎症与肿瘤模型研究某些特定蛋白在调控炎性疾病与肿瘤发生转移等过程中的功能与机制。工作以来,以第一作者及通讯作者身份发表多篇高水平SCI论文,包括PNAS(IF 10.59 1篇),Nature Communications(IF 14.8 2篇),Advanced Science(IF 16.8 3篇)及其它国内核心期刊论文。曾获首届湖北省青年拔尖人才2021,武汉市中青年医学骨干人才2019,武汉大学青年拔尖人才2017及武汉大学人民医院重点人才2017等多项荣誉称号。
    学术任职与荣誉 中华医学会伦理委员会 青年委员
    湖北省肿瘤心理专业委员会 常务委员
    湖北省抗癌协会肿瘤免疫治疗专业委员会 委员
    湖北省医学生物免疫学会科普委员会 委员
    湖北省微循环学会肿瘤专业委员会 委员
    武汉市医学会肿瘤专业委员会 委员
    教育履历  2004-2012年,武汉大学首届临床医学八年制毕业,博士学历
    工作履历 2012.07-2016.12武汉大学人民医院肿瘤III科主治医师
    2016.12-2020.07武汉大学人民医院肿瘤III科副主任医师
    2017.07-2018.06美国西南医学中心放疗科国家公派访问学者
    2019.07-2022.05武汉大学人民医院肿瘤III科副主任医师、副教授、硕士生导师
    2022.06-至今    武汉大学人民医院肿瘤III科科室副主任,主任医师,副教授,硕士生导师
    成果获奖
    代表性论著 1.Xiong TC, Wei MC, Li FX, Shi M, Gan H, Tang Z, Dong HP, Liuyu T, Gao P, Zhong B, Zhang ZD*, Lin D*. The E3 ubiquitin ligase ARIH1 promotes antiviral immunity and autoimmunity by inducing mono-ISGylation and oligomerization of cGAS. Nat Commun. 2022 Oct 10;13(1):5973. doi:10.1038/s41467-022-33671-5. PMID: 36217001; PMCID: PMC9551088.(最后通讯IF 14.8)
    2. Wang P#, Yang W#, Guo H, Dong HP, Guo YY, Gan H, Wang Z, Cheng Y, Deng Y, Xie S, Yang X, Lin D*, Zhong B*. IL-36g and IL-36Ra reciprocally regulate NSCLC progression by modulating GSH homeostasis and oxidative stress-induced cell death. Adv Sci, 2021, 2101501, doi: 10.1002/advs.202101501.(共通讯IF 16.8)
    3.Zhang M, Yang W, Wang P, Deng Y, Dong YT, Liu FF, Huang R, Zhang P, Duan YQ, Liu XD, Lin D*, Chu Q*, Zhong B*. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nat Commun. 2020 Nov 30;11(1):6119. doi: 10.1038/s41467-020-19973-6. PMID: 33257678. (共通讯IF 14.8)
    4.Lin D, Zhang M, Zhang MX, Ren YJ, Zhao Q, Jin J, Pan Z, Wu M, Shu HB, Dong C, Zhong B*. Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6. Proc Natl Acad Sci U S A. 2015, 112(36):11324-329.(第一作者IF 10.59)
    5.Ye L#, Zhang Q#, Liuyu T, Xu Z, Zhang MX, Luo MH, Zeng WB, Zhu Q, Lin D*, Zhong B*. USP49 negatively regulates cellular antiviral responses via deconjugating K63-linked ubiquitination of MITA. Plos Pathog, 2019, 15(4): e1007680.(IF 6.82)
    6.Zhang MX, Cai Z, Zhang M, Wang XM, Wang Y, Zhao F, Zhou J, Luo MH, Zhu Q, Xu Z, Zeng WB*, Zhong B*, Lin D*. USP20 promotes cellular antiviral responses via deconjugating K48-linked ubiquitination of MITA. J Immunol, 2019, 202(8): 2397-2406.(IF 5.4)
    7.Gao SF, Zhong B, Lin D*. Regulation of T helper cell differentiation by E3 ubiquitin ligases and deubiquitinating enzymes. Int Immunopharmacl. 2017, 42:150-156. (* corresponding author)(IF 3.8)
    Name  DANDAN LIN
    Date of birth Feb,1986
    Department  Cancer Center,Renmin Hospital,Wuhan University..
    Title Associte Professor, chief physician
    Email  236772452@qq.com
    TEL 13871180043
    Research Direction 1. Immunotherapy and targeted intervention 2. The molecular mechanism of gastroenterology
    Personal Profile He is mainly engaged in the diagnosis and treatment of cardiovascular diseases,and has been awarded 5 items for the National Natural Science Foundation, 10 items from the provincial science and Technology Department, the Provincial Education Commission and the Provincial Health Department.He has also involved in compiling the planning teaching material Internal Medicine. Besides,there are more than 100 articles published in the Journal of Chinese Cardiac Pacing and Electrocardiology and the Chinese Journal of Ultrasound Imaging,and more than 50 papers published by the first author, including nearly 30 SCI papers with more than 100 influencing factors.By now, he has educated 20 masters and 4 doctors. At present, there are 3 doctors and 5 Masters studying with him.
    Selected Publications 1.Xiong TC, Wei MC, Li FX, Shi M, Gan H, Tang Z, Dong HP, Liuyu T, Gao P, Zhong B, Zhang ZD*, Lin D*. The E3 ubiquitin ligase ARIH1 promotes antiviral immunity and autoimmunity by inducing mono-ISGylation and oligomerization of cGAS. Nat Commun. 2022 Oct 10;13(1):5973. doi:10.1038/s41467-022-33671-5. PMID: 36217001; PMCID: PMC9551088.(最后通讯IF 14.8)
    2. Wang P#, Yang W#, Guo H, Dong HP, Guo YY, Gan H, Wang Z, Cheng Y, Deng Y, Xie S, Yang X, Lin D*, Zhong B*. IL-36g and IL-36Ra reciprocally regulate NSCLC progression by modulating GSH homeostasis and oxidative stress-induced cell death. Adv Sci, 2021, 2101501, doi: 10.1002/advs.202101501.(共通讯IF 16.8)
    3.Zhang M, Yang W, Wang P, Deng Y, Dong YT, Liu FF, Huang R, Zhang P, Duan YQ, Liu XD, Lin D*, Chu Q*, Zhong B*. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nat Commun. 2020 Nov 30;11(1):6119. doi: 10.1038/s41467-020-19973-6. PMID: 33257678. (共通讯IF 14.8)
    4.Lin D, Zhang M, Zhang MX, Ren YJ, Zhao Q, Jin J, Pan Z, Wu M, Shu HB, Dong C, Zhong B*. Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6. Proc Natl Acad Sci U S A. 2015, 112(36):11324-329.(第一作者IF 10.59)
    5.Ye L#, Zhang Q#, Liuyu T, Xu Z, Zhang MX, Luo MH, Zeng WB, Zhu Q, Lin D*, Zhong B*. USP49 negatively regulates cellular antiviral responses via deconjugating K63-linked ubiquitination of MITA. Plos Pathog, 2019, 15(4): e1007680.(IF 6.82)
    6.Zhang MX, Cai Z, Zhang M, Wang XM, Wang Y, Zhao F, Zhou J, Luo MH, Zhu Q, Xu Z, Zeng WB*, Zhong B*, Lin D*. USP20 promotes cellular antiviral responses via deconjugating K48-linked ubiquitination of MITA. J Immunol, 2019, 202(8): 2397-2406.(IF 5.4)
    7.Gao SF, Zhong B, Lin D*. Regulation of T helper cell differentiation by E3 ubiquitin ligases and deubiquitinating enzymes. Int Immunopharmacl. 2017, 42:150-156. (* corresponding author)(IF 3.8)